Objective-The anti-inflammatory properties of the female sex hormone estrogen have been linked to a reduced incidence of cardiovascular disease. In the present study, we addressed whether estrogen could activate vasculoprotective mechanisms via annexin A1 (AnxA1) mobilization in human polymorphonuclear cells (PMNs). Methods and Results-Using whole-blood flow cytometry, we demonstrated that premenopausal women expressed higher levels of surface AnxA1 on circulating PMNs compared with males. This correlated with high plasma estrogen during the menstrual cycle. The addition of estrogen in vitro to male PMNs induced rapid mobilization of AnxA1, optimal at 5 ng/mL and a 30-minute incubation period; this effect was abolished in the presence of the estrogen receptor antagonist ICI182780. Estrogen addition to human PMNs induced a distinct AnxA1 hi CD62L lo CD11b lo phenotype, and this was associated with lower cell activation as measured by microparticle formation. Treatment of human PMNs with E 2 inhibited cell adhesion to an endothelial cell monolayer under shear, which was absent when endogenous AnxA1 was neutralized. Of interest, addition of estrogen to PMNs flowed over the endothelial monolayer amplified its upregulation of AnxA1 localization on the cell surface. Finally, in a model of intravital microscopy, estrogen inhibition of white blood cell adhesion to the postcapillary venule was absent in mice nullified for AnxA1. Conclusion-We unveil a novel AnxA1-dependent mechanism behind the inhibitory properties of estrogen on PMN activation, describing a novel phenotype with a conceivable impact on the vasculoprotective effects of this hormone. 
T he effects that sex hormones have on the processes regulating vascular inflammation have recently been reevaluated, identifying novel cell targets and pathways. These efforts are prompted by epidemiological evidence that gender affects the incidence of cardiovascular and inflammatory diseases. Compared with age-matched males, premenopausal, but not postmenopausal, females are protected against cardiovascular disease, 1 implicating a protective role for female sex hormones. Indeed, there is unequivocal evidence for vasoprotective and anti-inflammatory properties of estrogen (17-␤ estradiol [E 2 ]), 2, 3 raising the question of its cellular targets and molecular mechanisms. In the vasculature, estrogen has a direct positive effect on vascular function, improving blood flow, 4 and inhibiting vascular injury through regulation of endothelial-derived nitric oxide. 5 It is interesting to note that the timing of estrogen administration is a key factor in determining beneficial outcomes: when estrogen is given prophylactically, the extent of disease, its incidence, or both is reduced, but this protection is lost if administered following disease onset. 6 -9 In the context of acute inflammation, estrogen has been shown to be anti-inflammatory, suppressing the nuclear factor-B pathway, 10 as well as downregulating specific adhesion molecules on the vascular endothelium, 11 including the recently reported modulation of CD62P expression in the vessel wall. 12 Regulation of adhesion molecules by estrogen would lead to modulation of the infiltration of leukocytes into the vascular tissue. 12 Furthermore, estrogen reduces generation of the polymorphonuclear cells (PMN) chemoattractant cytokine-induced neutrophil chemoattractant-2␤ (CXCL3, GRO3), thereby inhibiting PMN migration. 13 It is accepted that estrogen modulation of cytokines and chemokines might underlie its regulatory properties in vascular inflammation, providing a potential explanation to clinical observations. Annexin A1 (AnxA1) is a 37-kDa protein with antiinflammatory properties in the context of experimental inflammation. 14 In human resting PMNs, AnxA1 is abundant in the cytoplasm, with only a small proportion present on PMN surface. On PMN activation, AnxA1 is rapidly mobilized to the cell surface, where it binds to its receptor, the G-protein coupled receptor formyl-peptide receptor 2/lipoxin A4 receptor (FPR2/ALX). 15 Following receptor ligation, AnxA1 is able to evoke a number of anti-inflammatory mechanisms, both in an autocrine and paracrine fashion, 14 inhibiting distinct stages of the leukocyte transmigration cascade. 16 -19 AnxA1 is also endowed with proresolving properties including promotion of efferocytosis of apoptotic PMNs. 14, 19 On activation, PMNs are also capable of releasing microparticles (also known as ectosomes). These are small (Ͻ1 m) membrane-bound structures that can be released from most cell types and express surface molecules derived from its parent cell. Recent evidence suggests that microparticles can induce cellular cross-talk and inhibit inflammatory responses. 20, 21 Of interest to us, PMN-derived microparticles expressing AnxA1 are capable of evoking anti-inflammatory actions. 22 Currently, there is little evidence indicating that estrogen affects PMN reactivity, and most studies have focused on the endothelial cell as the primary target to evoke vasculoprotective properties. Here, we started with the observation that premenopausal women express higher levels of AnxA1 on the PMN surface as compared with age-matched males, and this correlates with estrogen levels during the menstrual cycle. On these bases, we have studied the association between estrogen engagement of the AnxA1 pathway in human PMNs and cell activation in vitro and in vivo. We propose that this novel mechanism might at least contribute to the protective effects of estrogen in vascular inflammation.
Materials and Methods
Detailed information on protocols and ethics are in the Supplemental Methods, available online at http://atvb.ahajournals.org.
Cell Culture and Reagents
Unless otherwise stated, all cell culture reagents were obtained from Sigma-Aldrich (Poole, Dorset, United Kingdom). Human PMNs were isolated via density gradient as described. 17 PMNs (10 6 cells per test) or whole-blood aliquots (50 L) were incubated with E 2 before stopping reactions on ice. In selected experiments, the estrogen receptor (ER) antagonist ICI182780 was added for 10 minutes before E 2 . In other cases, E 2 was added at 5 ng/mL (30 minutes) before stimulation with formyl-Met-Leu-Phe (fMLF) (10 nmol/L).
Flow Cytometric Detection of Surface AnxA1 on Human PMNs
Cells or whole blood were incubated for 1 hour at 4°C with mouse anti-human AnxA1 (monoclonal antibody 1B, produced in-house 23 ) or anti-human FPR2/ALX (Genovac, Freiburg, Germany), using a 3-step protocol (Supplemental Methods). Briefly, after the first 1-hour incubation, cells were washed and incubated with a rabbit anti-mouse IgG fluorescein isothiocyanate-conjugated secondary antibody. Then, an additional 30-minute step with conjugated antibodies to CD16 (PE, clone eBioCB16), to L-selectin (PE-Cy5, clone DREG-56), or, in some samples, to CD11b (APC, clone ICRF44) was run.
For detection of plasma microparticles, after incubation with E 2 in the presence or absence of fMLF, platelet-free plasma was double stained for CD66b (PE, clone G10F5) (or IgM isotype control) to identify PMN-derived plasma microparticles and costained for AnxA1, FPR2/ALX, or CD62L. Beads (1 m each; Becton Dickinson, San Jose, CA) were also run, in selected samples, to control for microparticles size.
In all cases, 20 000 events were acquired by using a FACSCalibur flow cytometer (Becton Dickinson) and analyzed using FlowJo analysis software (version 9.2, Treestar Inc, Stanford, CA).
Western Blot Analysis
PMNs were separated into cytosolic and membrane fractions as reported, 24, 25 subjected to standard SDS-polyacrylamide gel electrophoresis, and transferred onto polyvinylidene difluoride membranes (Millipore, Watford, United Kingdom). These were incubated with monoclonal antibody 1B (1 g/mL) and horseradish peroxidaseconjugated goat anti-mouse IgG (Dako, Cambridge, United Kingdom). Proteins were detected using an enhanced chemiluminescence detection kit and visualized on Hyperfilm (GE Healthcare).
Determination of Plasma of E 2 , Progesterone, and Cortisol Concentrations
Blood was taken from females who were not on any oral contraceptives (for demographics, see Supplemental Table I ) at days 2, 12, 19 and 26 of individual menstrual cycles. All blood samples were taken between 10 and 11 AM. Plasma prepared from blood of female volunteers was tested for E 2 and progesterone concentrations using specific enzyme immunoassays (estradiol EIA kit, Invitrogen; progesterone and cortisol EIA, Cayman Chemical Co Inc, Ann Arbor, MI)
Flow Chamber Assay
Human umbilical vein endothelial cells (HUVECs) were cultured until they reached confluence and stimulated with 10 ng/mL tumor necrosis factor-␣ for 4 hours (Sigma-Aldrich). Isolated PMNs were incubated with vehicle, E 2 , or E 2 plus monoclonal antibody 1B for 30 minutes at 37°C before flow over HUVEC monolayer at a rate of 1 dyn/cm 2 for 8 minutes, as previously described. 17 PMN/HUVEC interaction in the flow chamber was monitored on 6 random fields recorded for 10 seconds. Analysis of total cell capture and rolling and firmly adherent PMNs was carried out off-line by manual quantification. In some cases, cells flowed over the HUVEC monolayers were collected and compared with resting (preflowed) or adherent PMNs for the extent of cell-surface AnxA1, CD62L, and CD11b expression using the flow cytometric protocol described above.
Intravital Microscopy of Leukocyte Recruitment on Mesenteric Postcapillary Venules
Male C57BL6 mice (AnxA1 ϩ/ϩ and AnxA1 Ϫ/Ϫ ; 4 weeks old) 26 were injected with either PBS or estradiol (100 ng/mouse, IP) 30 minutes before administration of IL-1␤ (10 ng/mouse, IP). After 2 hours, animals were anesthetized, and the mesenteric microvascular bed was exposed for analysis. Intravital microscopy was performed as previously reported. 18 A cautery incision was made along the abdominal region and the mesenteric vascular bed was exteriorized, placed on a viewing Plexiglas stage, and mounted on a Zeiss Axioskop FS with a water-immersion objective lens (magnification ϫ40, Carl Zeiss, Welwyn Garden City, United Kingdom) and an eyepiece (magnification ϫ10, Carl Zeiss). Mesenteries were superfused with thermostated (37°C) bicarbonate-buffered solution at a rate of 2 mL/min. When a suitable postcapillary venule was selected (diameter 20 to 40 m; straight vessel length 100 m), recording was started and kept up for a 3-minute period, during which adherent and emigrated leukocytes were counted.
Statistical Analyses
Data are expressed as meanϮSEM. The Student t test was used to compare 2 groups with parametric data distribution. For multiple comparison analyses, 1-and 2-way ANOVAs were carried out, with appropriate Dunnett, Tukey, or Bonferroni postcorrection tests. Probability values Ͻ0.05 were considered to be significant.
Results

E 2 Modulates AnxA1 Expression in Human PMNs
Analyses of AnxA1 expression in circulating cells of healthy volunteers revealed a consistent and significant increment in the fraction of AnxA1
ϩve PMNs in female donors ( Figure 1A ). Of 6 donors per gender, there was almost a doubling in cell surface AnxA1 on female PMNs (PϽ0.01). This difference was not seen in the expression of the AnxA1 receptor FPR2/ALX ( Figure 1A ). Analysis at the single cell level revealed a significant increase in AnxA1 extent of expression on PMNs taken from female donors (2-fold increase in mean fluorescence intensity units), whereas no differences between gender could be measured for FPR2/ALX or CD62L (Table) . These discrete, reproducible changes observed in PMNs purified from females, including the higher degree of AnxA1 surface expression at the cellular level, prompted us to investigate E 2 effects on human PMNs in vitro.
Male donors were used for these experiments. Concentrationresponse and time-course analyses revealed that 5 ng/mL E 2 (18 nmol/L) for 30 minutes yielded optimal mobilization of AnxA1 on the PMN surface (PϽ0.001; Figure 1B ), and this concentration was selected for subsequent experiments. To validate fluorescence-activated cell sorting analysis data of in vitro mobilization of AnxA1, Western blot analysis was also carried out. Figure 1C shows that presence of E 2 mobilized AnxA1 to the membrane fraction. Such an effect was due to engagement of the ER, because pretreatment with the antagonist ICI182780, significantly reduced the ability of E 2 to mobilize AnxA1 on PMN surface: Ϸ30% of PMNs were AnxA1 ϩve cells in the presence of E 2 , whereas, only 11% of PMNs were AnxA1 ϩve in the presence of the ER antagonist (10 to 100 mol/L ICI182780; PϽ0.001) ( Figure 1D ).
Estrogen Levels Correlate With AnxA1 Expression During the Menstrual Cycle
Whole-blood fluorescence-activated cell sorting analysis revealed peak AnxA1 mobilization on PMN surface occurred at day 12 of the cycle (22.6% AnxA1 ϩve versus 8.56%, 7.02%, and 2.30% at days 2, 19, and 26, respectively; PϽ0.001) ( Figure  2A ). No statistically significant fluctuation of FPR2/ALX or CD62L expression could be quantified across the cycle ( Figure  2A ). Plasma E 2 progesterone and cortisol levels were also measured confirming that E 2 levels were highest at day 12 of the cycle (325 versus 91 pg/mL at day 2), whereas progesterone peaked at day 26 (12.3 ng/mL). This peak in progesterone levels coincided with a resurgence in E 2 plasma levels at day 26 (Ϸ150 pg/mL) ( Figure 2B ). Plasma cortisol levels did not change throughout the time-course of the menstrual cycle. We obtained a good degree of correlation between PMN surface AnxA1 expression and plasma E 2 concentrations, with an r 2 value of 0.5628 ( Figure 2C , left panel). To test whether the correlation was affected by the presence of progesterone, day 26 values (peak for progesterone) were removed from the correlation graph, yielding an even higher r 2 value of 0.7655 ( Figure 2C , right panel). To assess the potential effect of progesterone on the ability of E 2 to mobilize AnxA1, we incubated whole blood from male donors with progesterone (10 ng/mL; menstrual cycle levels) and E 2 and observed a reduced ability to provoke AnxA1 mobilization by E 2 (PϽ0.05) ( Figure 2D ).
Profile of E 2 -AnxA1 Pathway in PMN Activation In Vitro
The results so far have shown the effects of E 2 on AnxA1 mobilization in the absence of cell activation. To investigate the potential effects of E 2 associated AnxA1 externalization, we carried out a series of in vitro experiments in which whole blood was either pretreated with fMLF (10 nmol/L, 20 minutes) followed by E 2 treatment (5 ng/mL, 30 minutes), or pretreated with E 2 followed by fMLF (in comparison with vehicle and single-treatment controls). Figure 3A shows box-and-whisker plots of this set of experiments. As previously observed, E 2 treatment signifi- Estrogen confers an anti-inflammatory phenotype to human polymorphonuclear cells (PMNs). A, Male whole blood was treated with either formyl-Met-Leu-Phe (fMLF) (10 nmol/L) for 20 minutes, E 2 (5 ng/mL) for 30 minutes, or a combination of treatments consisting of fMLF followed by E 2 or pretreatment with E 2 followed by fMLF. All blood aliquots were kept at 37°C for a total of 50 minutes of incubation time. Flow cytometry allowed quantification of the degree of expression of annexin A1 (AnxA1), formyl-peptide receptor 2/lipoxin A4 receptor (FPR2/ALX), CD62L, CD11b, and CD66b on the PMN surface. Data are meanϮSEM of 6 experiments conducted with different blood preparations. *PϽ0.001 compared with vehicle control (1-way ANOVA with the Dunnett postcorrection); **PϽ0.001. B, Representative histograms depicting the mean fluorescence intensity units for AnxA1, CD66b, and CD62L from the experiments presented in A. Gray histograms indicate isotype controls (IgG1 for AnxA1 and CD62L, and IgM for CD66b).
cantly mobilized AnxA1 to PMN surface compared with vehicle control (PϽ0.001). AnxA1 externalization was not observed in fMLF treatment alone or when PMNs were pretreated with fMLF before E 2 ( Figure 3A) . In contrast, pretreatment of PMNs with E 2 before fMLF resulted in significant mobilization of AnxA1 similar to levels seen in E 2 treatment alone. Analysis of FPR2/ALX expression indicated lack of externalization on E 2 treatment but an upregulation post-fMLF, irrespective of the presence of E 2 (PϽ0.001 for all 3 treatment groups). Figure 3B reports representative histograms from these experiments, showing AnxA1 expression alongside that of CD66b and CD62L. Analysis of CD66b expression revealed a significant augmentation in PMN surface expression, when cells were treated with fMLF alone or given as pretreatment. This was not observed, however, with vehicle or E 2 (alone or as pretreatment). Vehicle and E 2 alone had no effect on CD62L shedding, whereas fMLF treatment caused significant CD62L-shedding, which was unaffected by with E 2 addition. Interestingly, pretreatment of PMNs with E 2 (5 ng/mL) did not rescue the cells from CD62L shedding but did maintain low expression of the ␤ 2 -integrin CD11b when compared with vehicle and E 2 treatment alone ( Figure 3A and 3B) . Therefore, E 2 can selectively modulate PMN stimulation induced by fMLF.
Next, we measured neutrophil-derived microparticles as a test for E 2 to inhibit downstream PMN activation, and we used the plasma from blood treated as in Figure 3 . Microparticles were identified according to their size (and using 1-m beads; see Supplemental Figure I ). Treatment of PMNs with fMLF promoted a significant release of CD66b ϩve microparticles compared with vehicle control (PϽ0.001). Addition of E 2 prevented microparticle generation elicited by fMLF, and this time, the hormone was active even when added after the stimulus ( Figure 4A ). These responses are shown in representative histograms ( Figure 4B ). Microparticles generated in these experimental conditions were characterized further quantifying specific antigens on a per-microparticle basis, reporting it as mean fluorescence intensity units. 
Treatment of fMLF alone led to a 2-fold increase in the expression of AnxA1 on CD66b
ϩve microparticles compared with vehicle (PϽ0.001). This response was insensitive to cell exposure to E 2 (5 ng/mL) following fMLF, whereas estrogen was ineffective when given alone ( Figure 4C ). In contrast, and in line with the global data on microparticle formation, pretreatment with E 2 abrogated fMLF-induced generation of AnxA1/CD66b double positive microparticles ( Figure 4C ). The extent of expression of FPR2/ALX on PMN-derived microparticles was marked even in vehicle-treated cells and only marginally modulated by the treatments. In contrast, CD62L expression (mean fluorescence intensity units) was reduced by E 2 only when added before fMLF ( Figure 4C ). Collectively, these data indicated that E 2 can modulate PMN activation recorded via microparticle generation and can modify, at least in part, some of the proteins displayed on these microstructures.
E 2 Modulates PMN Reactivity Under Flow via Endogenous AnxA1
In the next series of experiments, we wanted to determine whether E 2 could modulate PMN activation, and hence inflammatory responses, in an AnxA1-dependent fashion. To model the impact of E 2 -treated PMNs in vascular inflammation, we used the flow chamber assay. Following HUVEC activation by tumor necrosis factor-␣, PMNs from healthy males treated with vehicle, E 2 , or E 2 plus an anti-AnxA1 neutralizing antibody were flowed over the monolayer.
Cell incubation with E 2 did not affect the ability of the PMNs to come in contact with the monolayer and hence did not affect cell capture (the total number of interacting cells; Figure 5 , top). However, a selective interference with the extent of PMN adhesion resulted in Ϸ3-fold decrease ( Figure  5 , middle; PϽ0.001). This effect was significantly lost when PMNs were coadministered with the AnxA1 neutralizing antibody and E 2 . There were no significant differences in the capture or rolling of PMNs between the 3 treatments ( Figure  5A , bottom). Figure 5B displays representative images captured from these experiments.
The experiments of flow chamber assay allowed us to investigate the phenotype of the E 2 -treated PMNs that had encountered the inflamed endothelium in the flow chamber but did not adhere, as well as cells that had adhered to the endothelium. Addition of E 2 (5 ng/mL; 30 minutes) to PMNs that had flowed over the HUVEC monolayer resulted in higher levels of AnxA1 on their surface ( Figure 6B ) compared with hormone addition to resting PMNs (preflow in Figure 6A ; PϽ0.05). These changes in AnxA1 were not reflected by any detectable change in CD62L ( Figure 6A and 6B). In contrast, although postflow PMNs displayed higher CD11b levels to static (preflow) PMNs, the addition of E 2 (5 ng/mL; 30 minutes) significantly attenuated this cellular response ( Figure 6A and 6B, bottom) .
We also recovered postadherent PMNs (dislocating cells by increasing shear) and detected much higher AnxA1 levels in vehicle-treated cells (reminiscent of our old observations 16 ), and this could be partially modulated by E 2 (5 ng/mL; 30 minutes) ( Figure 6C ). CD11b was higher in postadherent PMNs and was no longer susceptible to the addition of the hormone.
E 2 Modulates In Vivo PMN Reactivity via Endogenous AnxA1
The effect of E 2 on PMN recruitment under flow was also assessed in vivo using the inflamed microvasculature of the mesentery. This model was chosen because of the tonic buffering role exerted by endogenous AnxA1. 25 Treatment of wild-type mice with interleukin (IL)-1␤ alone caused a significant increase in cell adhesion and emigration compared with vehicle control, as assessed at 2 hours postcytokine ( Figure 5A, PϽ0.001) . Pretreatment of the animals with E 2 (100 ng IP; Ϫ30 minutes) significantly attenuated the effect of IL-1␤ in terms of both cell adhesion and emigration (PϽ0.001). Figure 5B shows representative images of the mesenteric microcirculation of wild-type mice treated with IL-1␤ in the presence or absence of E 2 . Importantly, modulation of this inflammatory event by E 2 was dependent on endogenous AnxA1 because this hormone was ineffective when tested in AnxA1 Ϫ/Ϫ male mice (Supplemental Figure  II) . Hemodynamic parameters can be seen in Supplemental Table II. 
Discussion
In the present study, we provide evidence that the female sex hormone estrogen exerts inhibitory effects on human PMNs, which translate to anti-inflammatory properties in vascular inflammation and provide a strong indication for a functional association with endogenous AnxA1. Together, these results readdress the target for the anti-inflammatory mechanisms of estrogen, indicating that, besides the vascular wall, this hormone can have marked effects on the blood-borne leukocyte.
The anti-inflammatory nature of female sex hormones has long been noted, and it is well established that, for instance, Figure 6 . E 2 -treated polymorphonuclear cells (PMNs) postflow had a marked increase in annexin A1 (AnxA1) surface expression, but low CD11b. PMNs were treated as described in Figure 5 . Preflow (A), postflow (B), and postadherent (C) PMNs were stained for AnxA1, CD62L, and CD11b expression on the plasma membrane. PϽ0.001 compared with vehicle (Student t test). Representative histograms are also shown. *PϽ0.05; ***PϽ0.001. inflammatory and cardiovascular diseases are exacerbated in postmenopausal women. 1 More specifically, recent studies have shown postmenopausal women present increased levels of adipokines (eg, serum amyloid protein A 27 ), as well as proinflammatory cytokines (eg, IL-8, 28 ) in plasma, all of which increase the risk of cardiovascular diseases. The present study was prompted by the observation that a higher degree of cell surface AnxA1 could be measured on circulating PMNs of premenopausal female volunteers compared with age-matched males.
A previous study reported the detection of the cell surface AnxA1 in blood leukocytes, specifically PMNs, which correlated with plasma cortisol. 29 These latter results presented a functional, well-characterized association between glucocorticoids and cellular expression of the anti-inflammatory protein, AnxA1. 30 Here our unexpected observation of sexual dimorphism, specifically for the blood PMNs, prompted us to perform more detailed analyses during the course of the menstrual cycle. These new data indicate that cell surface AnxA1 in circulating PMNs is selectively modulated by levels of circulating hormones, with a significant and robust correlation to plasma estrogen levels but neither progesterone nor cortisol. Such an association was not consequent to a global, nonselective change in PMN phenotype, because AnxA1 cell surface expression was discretely augmented in correlation with peak of estrogen level without changes in cell surface FPR2/ALX or CD62L.
Estrogen is known to modulate a variety of responses in target cells that could have an impact on the intensity of an experimental inflammatory response. For example, estrogen regulates PMN recruitment by inhibiting the chemokine cytokine-induced neutrophil chemoattractant-2␤ 13 and other cytokines, likely consequent to a suppression the nuclear factor-B pathway. 10 Such a complex network of effects is not surprising in view of the pleiotropic action of this hormone. In the context of vascular inflammation, the majority of studies have focused on the endothelium. Estrogen maintains vascular tone by mediating key endothelial-derived factors. For example, in vitro treatment on endothelial cells with estrogen augments the production of the antiinflammatory autocoids nitric oxide, 5 prostacyclin, 31 and endothelial-derived hyperpolarizing factor. 32 The dichotomy between genders made the PMNs the focus of the present study.
We found that there was a distinct and reproducible mobilization of AnxA1 in human PMNs on incubation with estrogen; the effect was nongenomic, optimal at 30 minutes, and mediated by classical ERs as demonstrated by the use of the nonselective ER antagonist ICI182780. The data were reassuring in view of the well-documented presence of ER-␣ and ER-␤ in human PMNs. 33, 34 Moreover, a microarray study in the rat has reported a directly associated ER binding with gene regulation of AnxA1 in blood leukocytes. 34 Together with our new data, we can propose that this hormone produces nongenomic and genomic regulation of this mediator of endogenous anti-inflammation.
Our ex vivo measurements showing that high AnxA1 correlate with high E 2 (but not cortisol) during the menstrual cycle added support to our in vitro findings. In the timecourse analyses, we chose day 12, as E 2 is the only hormone that is high during this period of the menstrual cycle. However, E 2 levels remain high for a few days during the menstrual cycle. It is tempting to propose that the antiinflammatory effects of E 2 (via AnxA1) could be explained by the fact that at days 13 and 14, when E 2 levels remain high, follicle-stimulating hormone and luteinizing hormone are also high. Because both follicle-stimulating hormone and luteinizing hormone have been positively correlated with AnxA1 29 E 2 could act in concert with follicle-stimulating hormone and luteinizing hormone and exert their antiinflammatory actions by promoting AnxA1 mobilization. Of course, this hypothesis would need to be substantiated by future investigations.
In the human PMN, AnxA1 represents a substantial amount of the intracellular proteins, being calculated to be between 2% and 4%. 16, 35 We have gathered evidence for the existence of at least 2 pools of the protein in resting PMNs, one cytosolic and the other associated with subcellular organelles, such as gelatinase and azurophilic granules. 36 More recent studies indicate that these distinct pools of intracellular AnxA1 can be mobilized in a stimulus dependent fashion; thus, cell activation consequent to outside-in signaling (eg, after cell adhesion) exports the granule/vesicular pool of the protein. 16, 36 In contrast, pharmacological treatment with dexamethasone, 37 cromones, 38 or other soluble compounds 25, 39 appears to engage the cytosolic pool of the protein. The latter process seems relevant to the effects of estrogen on the PMN treatment, because analyses of specific markers for intracellular granules (eg, CD66b or CD11b) failed to detect modulation of cell surface expression at concentration, and incubation time, optimal for E 2 promotion of AnxA1 mobilization. Of interest, recent work has demonstrated existence of a partial similarity between glucocorticoids and estrogens with respect to gene modulation in the human PMN, observing also how an ER antagonist can impact on the biological properties of glucocorticoids in vitro 40 and in vivo. 41 The present study extends the potential for this crosstalk, or at least shared properties, between these 2 classes of hormones to rapid nongenomic modulation of AnxA1 expression.
The functional relevance of estrogen-induced AnxA1 externalization was initially investigated in vitro, monitoring classical PMN activation markers. Preincubation of human PMNs with estrogen inhibited cell activation by formylated peptides, in a selective fashion, because significant inhibition was quantified against fMLF-induced CD11b and CD66b upregulation but not CD62L shedding. Chronologically, the mechanism activated by estrogens must precede the cell simulation with fMLF because the hormone was inactive when added after the PMN activator. Indeed, a distinct PMN phenotype (AnxA1 hi CD62L lo CD11b lo ) is apparent in estrogenpretreated PMNs, as seen in several settings (see below), prompting us to suggest the existence of an E 2 -generated anti-inflammatory PMN phenotype that may have an impact on further cell recruitment to sites of inflammation. 42, 43 The fact that estrogen could alter specific pathways in the human PMN can also be deduced from the lack of modulation of fMLF-induced FPR2/ALX upregulation. This receptor is known to be expressed in a variety of granules 44 and to be upregulated on cell trafficking 45 ; such a pattern is grossly similar to what described for AnxA1, yet it was not modulated by estrogen. This apparent lack of modulation of cell surface FPR2/ALX expression was also evident in circulating cells taken from healthy subjects.
Our analyses of PMN activation were concluded by quantifying the production of PMN-derived microparticles, a response that is gaining momentum both with respect to biological functions 22, 39, 46 and suitability as disease biomarker. 46, 47 In line with the results obtained with CD11b and CD66b, addition of estrogen before fMLF reduced the production of PMN-derived microparticles, quantified as CD66b ϩve microstructures. Collectively, these results indicate that estrogen application to human PMNs-before stimulation-significantly attenuates cell activation. We propose that modulation of PMN responsiveness by estrogen could be at least contributory, in association with the reported effects on vascular wall reactivity, to gender specificity with respect to gender-specific disease penetrance observed for cardiovascular pathologies.
This proposition, and its link to endogenous AnxA1, is corroborated by the experiments of flow chamber where the specific effect of E 2 -treated PMNs on inflamed endothelium was tested. The antiadhesive effect of AnxA1 on PMNs under flow has been well documented by our group. 17, 38 We found that in comparison with vehicle control, there was a significantly lower degree of PMN adhesion to the inflamed endothelium with E 2 -treated PMNs-an effect that was lost when AnxA1 was neutralized. These data were supported by in vivo experiments where the effect of estrogen on the inflamed microcirculation was tested. A real-time protocol of intravital microscopy was applied whereby the mesenteric vasculature was inflamed by administration of IL-1␤. Intraperitoneal treatment of male mice with estrogen produced a marked attenuation of the extent of leukocyte adhesion and emigration. This finding is aligned with the antimigratory and anti-inflammatory properties of this hormone as demonstrated in ovariectomized animals, where leukocyte recruitment was significantly increased. 12 These experiments provide a crucial functional link between the variety of analyses performed with human subjects and cells and the potential pathophysiological relevance, noting also that the significant attenuation of white blood cell recruitment onto the postcapillary venule vessel wall, resulting from estrogen administration, was absent in AnxA1 Ϫ/Ϫ mice. Finally, we wanted to determine whether E 2 -treated PMNs that had encountered the inflamed endothelium under flow but did not adhere had a phenotype similar to our in vitro experiments. Analysis of AnxA1 on postflow PMNs suggests that we might have underestimated the effect of E 2 on AnxA1 mobilization: there was a 3-fold increase in AnxA1 expression on E 2 -treated postflow PMNs compared with the preflow PMNs (static incubation). This is a novel observation, and it stresses the importance of testing modulation of the AnxA1 pathway 14 in the presence of shear. It is therefore plausible that the externalization of AnxA1 induced by the classes of drugs listed above (eg, glucocorticoids, cromones, and more) might be much more pronounced in intravascular settings, where the PMN is subjected to shear stress.
In line with our in vitro results in static settings, there was a significant attenuation of CD11b expression on postflow E 2 -treated PMNs, compared with their adherent counterparts. A similar effect has been observed in eosinophils, where glucocorticoid-induced AnxA1 mobilization resulted in inhibition of ␤ 2 integrin-intercellular adhesion molecule-1 interactions in eosinophils and to a lesser degree PMNs. 48 Taken together, these results suggest that E 2 has 2 distinct effects on the PMN: under noninflamed "normal" conditions, E 2 induces a modest increase of surface AnxA1 with no modulation of CD11b, which could be thought of as priming mechanism. However, under inflamed, nonstatic conditions, E 2 is capable of mounting a pronounced protective antiinflammatory response by augmenting AnxA1 surface expression and modulating CD11b expression.
In conclusion, we unveil a novel mechanism whereby AnxA1 externalization can drive estrogen-regulated antiinflammatory processes in PMN biology. It remains to be seen whether such an association could also be extended to other properties recently ascribed to AnxA1, such as modulation of the life span of migrated neutrophils 37, 49 and of their removal by phagocytes. 19, 50 
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